

Contents

Preface *xiii*

A Personal Foreword *xvii*

1	Chemical Strategies for Evaluating New Drug Targets	1
	<i>Adrian J. Carter, Raina Seupel, Paul E. Brennan, Michael Sundström, Andrea Introini, and Anke Mueller-Fahrnow</i>	
1.1	Introduction	1
1.2	Use Cases and Case Studies for Chemogenomic Compounds and Chemical Probes	5
1.2.1	Chemogenomic Libraries	5
1.2.2	Inactive Control	6
1.2.3	Use of Biological Target Panels and Profiling	8
1.3	Development of Chemical Probes	10
1.3.1	From BIX01294 to EPZ035544: Development and Improvement of G9a/GLP Inhibitors	10
1.3.2	Development of BRD9 Inhibitors	12
1.4	Compound-Based Target Evaluation with Patient-Derived Cells	14
1.4.1	Compound-Based Target Evaluation	14
1.4.2	Patient-Derived Cell Assays	16
1.4.3	Target Evaluation Approach	16
1.4.4	Case Story: Inflammatory Bowel Disease (IBD) Tissue Platform	18
1.5	Summary and Outlook	19
	References	20
2	Affinity-Based Chemoproteomics for Target Identification	25
	<i>Annika Jenmalm Jensen and Ivan Cornella Taracido</i>	
2.1	Introduction	25
2.2	Small Molecule Phenotypic Mechanism of Action Elucidation	29
2.3	Quantitative High-Resolution Mass Spectrometry as a Protein Detection Read-Out	30
2.4	In-Lysate Affinity-Based Chemical Proteomics	33
2.4.1	Design of the Affinity Probe	34
2.4.2	General Experimental Pulldown Workflow	36
2.4.3	Limitations	38

2.5	In-Cell Light-Activated Affinity-Based Chemoproteomics	39
2.5.1	Design of the Reactive Photoaffinity Probe (PAL Probe)	40
2.5.2	General Experimental Workflow	40
2.5.3	Limitations	43
2.6	Target Validation and Mode of Action	43
2.7	Concluding Remarks	45
	References	46
3	Activity-Based Protein Profiling	51
	<i>Nattawadee Panyain, Cassandra R. Kennedy, Ryan T. Howard, and Edward W. Tate</i>	
3.1	Introduction	51
3.2	Activity-Based Probe (ABP) and Affinity-Based Probe (AfBP) Design	53
3.2.1	Warheads (Reactive Groups)	53
3.2.1.1	Electrophilic Warheads	55
3.2.1.2	Photocrosslinking Warheads	55
3.2.2	Reporter Tags	56
3.2.3	Linkers	56
3.2.4	Bioorthogonal Ligation Chemistry	57
3.2.4.1	Staudinger Ligation	58
3.2.4.2	Copper(I)-Catalysed Azide-Alkyne Cycloaddition (CuAAC)	58
3.2.4.3	Strain-Promoted Azide-Alkyne Cycloaddition (SPAAC)	59
3.2.4.4	Diels–Alder Reaction	59
3.3	Chemical Proteomic Workflow	60
3.3.1	Quantitative Proteomics by Mass Spectrometry	61
3.3.1.1	Label-Free Quantification (LFQ)	61
3.3.1.2	Chemical Labelling Quantification	61
3.3.1.3	Metabolic Labelling Quantification	63
3.4	ABPP Applications and Case Studies	63
3.4.1	Case Study 1: Activity-Based Protein Profiling as a Robust Method for Enzyme Identification and Screening in Extremophilic Archaea	65
3.4.2	Case Study 2: Failed Clinical Trial of a Fatty Acid Amide Hydrolase (FAAH) Inhibitor	68
3.4.3	Case Study 3: Target Identification of Small Molecule Inhibitors	71
3.4.3.1	New Target Profiling for Sulforaphane	71
3.4.3.2	Profiling USP Inhibitors in Human Cell Lines as Potential Therapeutic Molecules	73
3.4.4	Case Study 4: Fragment-Based Ligand Discovery Aided by Photoaffinity Labelling	74
3.4.5	Case Study 5: Quenched Fluorescent Activity-Based Probe (qABP) Design and Application in Protein Localization	80
3.5	Summary	82
	References	83

4	Kinobeads: A Chemical Proteomic Approach for Kinase Inhibitor Selectivity Profiling and Target Discovery	97
	<i>Maria Reinecke, Stephanie Heinzlmeir, Mathias Wilhelm, Guillaume Médard, Susan Klaeger, and Bernhard Kuster</i>	
4.1	Kinase Inhibitor Target Deconvolution Using Chemical Proteomics	97
4.1.1	Polypharmacology of Small Molecule Kinase Inhibitors	97
4.1.2	Chemoproteomic Profiling of Kinase Inhibitors	100
4.1.3	Tips and Tricks Regarding Chemoproteomic Assay Development	103
4.2	Detailed Kinobeads Protocol	105
4.2.1	Cell or Tissue Lysate	107
4.2.2	Affinity Matrices	107
4.2.3	Kinobeads Competition Assay	110
4.2.4	Mass Spectrometry	111
4.2.5	Peptide and Protein Identification and Quantification	112
4.2.6	Data Analysis	112
4.3	Application Examples for Kinobeads	113
4.3.1	Expanding the Target Space of Kinobeads	113
4.3.2	Target Space Deconvolution of Small Molecule Kinase Inhibitors	116
4.3.3	Opportunities Arising from Inhibitor Polypharmacology: Drug Repositioning	120
4.3.4	Chemoproteomic-Guided Medicinal Chemistry	121
4.4	Kinobeads, Inhibitors, and Drug Discovery: Where Are We Heading?	123
4.4.1	What Is a Good Drug?	123
4.4.2	How Can We Discover New Drugs in the Future?	124
4.4.3	The Yin and Yang of Chemoproteomic-Guided Drug Discovery	124
	Acknowledgments	125
	References	125
5	Label-Free Techniques for Target Discovery and Validation	131
	<i>Daniel Martinez Molina and Michael Dabrowski</i>	
5.1	Introduction	131
5.2	CETSA: How It All Began	132
5.3	The CETSA Formats	136
5.3.1	CETSA Classics	136
5.3.2	CETSA HT	138
5.3.3	CETSA MS	140
5.4	Target Discovery	142
5.4.1	Generation of Active Hit Molecules	142
5.4.2	Tool Generation (Small Screens to Identify Tool Compounds)	143
5.4.3	Target Classes That Are In and Out of Scope and Difficult Targets	143
5.4.4	Focused or Iterative Library Screening	144

5.4.5	Fragment Library Screening	144
5.4.6	Hit Confirmation	145
5.4.7	Phenotypic Hit Deconvolution to Discover Targets	145
5.5	Target Validation	147
5.5.1	Binding Modes	147
5.5.2	Selectivity, Specificity, and Safety	148
5.5.3	Translation Bench to Bedside (via Animals)	149
5.6	Conclusion	150
	References	151
6	Reverse Translation to Support Efficient Drug Target Selection and Stratified Medicine	153
	<i>Lauren Drowley and Martin Armstrong</i>	
6.1	Introduction: the Challenge	153
6.2	Genetics to Date in Drug Discovery	154
6.3	Genetic Strategies for Target Discovery	156
6.3.1	GWAS	158
6.3.2	Rare Disease Genetics	160
6.3.2.1	Rare Mutation → Rare Disease Drug Discovery	161
6.3.2.2	Rare Mutation → Common Disease Drug Discovery	161
6.3.3	Somatic Mutations	162
6.3.4	Analytical Approaches	163
6.4	Functional Validation	164
6.4.1	Prioritization of Putative Mutations	165
6.4.2	Determining Functional Consequence of Mutation	165
6.4.2.1	Publicly Available Data	165
6.4.2.2	Systems Biology	166
6.4.2.3	Model Systems: 'The Tissue Is the Issue'	168
6.4.3	Druggability: From Validation of a Gene to a Druggable Target	169
6.5	Forward-Looking Perspectives	170
6.5.1	Molecular Taxonomy of Disease	171
6.5.2	Precision Medicine	171
6.5.3	Data Integration	172
6.6	Conclusion	173
	References	173
7	Elucidating Target Biology and Drug Mechanism of Action Across Human Cell-Based Model Systems	179
	<i>John C. Dawson and Neil O. Carragher</i>	
7.1	Introduction	179
7.2	Advances in Human Cell-Based Model Development	182
7.2.1	Next-Generation Sequencing (NGS)	183
7.2.2	CRISPR Genome Editing	184
7.2.3	Induced Pluripotent Stem Cell Biology	184
7.2.4	3D Cell and Organoid Models	185
7.2.5	Microfluidic and Organ-on-a-Chip Devices	186
7.2.6	<i>In Vivo</i> Imaging	188

7.2.7	High-Content Imaging	190
7.3	Multiparametric High-Content Phenotypic Profiling of Target Biology and Drug Mechanism of Action	191
7.3.1	High-Content Cell Painting in Functional Genomics	193
7.3.2	Integration of Multiparametric High-Content Imaging with Chemoinformatics	195
7.3.3	Guiding Chemical Design and Target Selectivity from Multiparametric High-Content Analysis	195
7.4	Target-Annotated Compound Libraries for Phenotypic Screening and MOA Determination	196
7.5	Quantitative Pathway Profiling Across New Model Systems	197
7.5.1	Pathway Profiling at the Gene Transcription Level	198
7.5.2	Dynamic Post-Translational Pathway Profiling Across Dose–Response and Time-Series Studies	199
7.6	Conclusions	202
	References	203
8	Cell Biology Methods in Target Validation	211
	<i>Manfred Koepl and Simon Wöhrle</i>	
8.1	Introduction	211
8.2	Biomarkers	211
8.2.1	Direct Target Engagement Biomarkers	212
8.2.2	Indirect Target Engagement Biomarkers and Pathway Biomarkers	213
8.2.3	Response Biomarkers	214
8.2.4	Correlation of Biomarkers	214
8.3	Direct Evidence to Show That Modulation of a Target Leads to a Cellular Response	219
8.4	Direct Evidence That Target Modulation Is Responsible for Cellular Responses by Mutations Conferring Sensitivity to Existing Drugs	219
8.4.1	The ‘Bump-and-Hole’ Approach to Generate Sensitivity to Small Molecule Inhibitors	219
8.4.2	Chemogenomic Approaches for Inducible Degradation of Protein Targets	222
8.5	Resistance Conferring Mutations	226
	References	229
9	Genetic Manipulation/Modulation for Target Discovery and Validation	233
	<i>Christophe Lanneau, Georges Kalouche, Xinming Cai, Francois Lo-Presti, and Christoph Potting</i>	
9.1	Introduction	233
9.2	Overview of the Development of Leading Genetic Manipulation Technologies	234
9.2.1	RNAi, ZFNs, and TALENs	234
9.2.2	Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)	237

9.3	Considerations for Designing and Interpreting CRISPR Experiments	238
9.3.1	Methodological Considerations for Genetic Manipulation by the CRISPR/Cas Technology	238
9.3.2	Choosing a Cellular Model: Biological and Genomic Aspects	239
9.3.3	gRNA Design	242
9.3.3.1	Identification of Target Locations	242
9.3.3.2	Selection of Spacer Sequences	245
9.3.3.3	Predictive Tools	247
9.3.4	Successful Application of the CRISPR/Cas Technology	249
9.3.4.1	Delivering CRISPR Reagents to Target Cells	249
9.3.4.2	Check for Anticipated Knockout/Knock-In	252
9.4	Further Developments of the CRISPR/Cas Technology Facilitates Additional Modes of Genetic Perturbation	253
9.4.1	CRISPRi	253
9.4.2	CRISPRa	253
9.4.3	Base Editing	254
9.5	The CRISPR/Cas Technology in Target Discovery and Validation	254
9.5.1	CRISPR/Cas Technology for Early Target Validation	254
9.5.2	CRISPR Screens and Use for Target Discovery	255
9.5.3	CRISPR Screens: General Principle and Considerations	256
9.5.4	Selected Examples of Target Discovery Using CRISPR Screens to Illustrate the Breadth of Applications	258
9.6	Application of CRISPR Genome Editing in Immunology Studies	260
9.7	Concluding Remarks	262
	References	263
10	Computational Approaches for Target Inference	277
	<i>Gerhard Hessler, Christoph Grebner, and Hans Matter</i>	
10.1	Introduction	277
10.2	Data Annotation for Target Identification	278
10.3	<i>In Silico</i> Methods for Target Identification	280
10.3.1	2D Similarity Methods for Target Inference	283
10.3.2	3D Similarity Methods for Target Inference	289
10.3.3	Fragment-Based Approaches	290
10.3.4	QSAR Models and Machine Learning	292
10.3.5	Experimentally Derived Molecular Descriptors	297
10.3.6	Structure-Based Screening	299
10.3.7	Protein–Protein and Ligand–Target Networks	302
10.4	Practical Considerations	304
10.5	Conclusion	307
	References	308
11	Bioinformatic Approaches in the Understanding of Mechanism of Action (MoA)	323
	<i>Maria-Anna Trapotsi, Ian Barrett, Ola Engkvist, and Andreas Bender</i>	
11.1	Bioinformatics: Introduction	323

11.1.1	Some Definitions: Mechanism Versus Mode of Action	323
11.1.2	Importance of MoA and Target Prediction in the Drug Discovery Process	324
11.1.3	Different Levels of Information in Mechanism of Action and Target Prediction	325
11.2	Transcriptomics Data and Databases	326
11.2.1	Biological Background of the Transcription Process	326
11.2.2	Connectivity Map: CMap	327
11.2.2.1	Applications of CMap in MoA Deconvolution	328
11.2.3	Library of Integrated Network-Based Cellular Signatures (LINCS)	331
11.2.3.1	LINCS L1000 Data Exploration	332
11.2.3.2	Applications of L1000 Data in MoA Understanding	333
11.3	Pathway Data and Databases	339
11.3.1	What Is a Pathway?	339
11.3.2	Process of Pathway Analysis	341
11.3.3	Pathways in the Understanding of MoA	345
11.3.3.1	Methodology 1: MoA Analysis by Annotating Predicted Compounds' Targets with Pathways	345
11.3.4	Combination of Gene Expression and Pathway Data	346
11.3.4.1	Methodology 2: Construction of Drug Networks (DNs) with Gene Expression Data and Pathway Annotations	346
11.3.4.2	Methodology 3: Link Drug Target and Pathway Activation to Understand MoA	347
11.4	Image-Based Data	348
11.4.1	Image Data and Where to Extract Them From	348
11.4.2	Application of Image-Based Data in Target Prediction and Better Understanding of MoA	350
11.4.2.1	Methodology 1: Clustering of Compounds Based on Cell Morphology	350
11.4.2.2	Methodology 2: Use of Image-Based Data in the Development of a Cell Morphology Database That Can Facilitate Drug Target Identification	350
11.4.2.3	Methodology 3: Use of Image Data in Drug Repositioning and Biological Activity Prediction	353
11.4.2.4	Methodology 4: Association of Genes with Context-Dependent Morphology Alterations from Cells Exposed to Chemical or Genetic Perturbations for MoA Elucidation	354
11.5	Conclusions	357
	Acknowledgement	357
	References	357